Modality
ADC
MOA
MALT1i
Target
PRMT5
Pathway
Complement
CTCLMMParkinson's
Development Pipeline
Preclinical
~Mar 2014
→ ~Jun 2015
Phase 1
~Sep 2015
→ ~Dec 2016
Phase 2
~Mar 2017
→ ~Jun 2018
Phase 3
Sep 2018
→ Apr 2031
Phase 3Current
NCT04613495
2,893 pts·Parkinson's
2023-11→2031-04·Recruiting
NCT08767975
228 pts·CTCL
2019-12→2029-01·Recruiting
NCT08330908
538 pts·Parkinson's
2018-09→2027-12·Recruiting
+1 more trial
4,511 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2027-03-2412mo awayPh3 Readout· Parkinson's
2027-12-231.7y awayPh3 Readout· Parkinson's
2029-01-122.8y awayPh3 Readout· CTCL
2031-04-085.0y awayPh3 Readout· Parkinson's
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P3
Recruit…
P3
Recruit…
P3
Not yet…
P3
Recruit…
Catalysts
Ph3 Readout
2027-03-24 · 12mo away
Parkinson's
Ph3 Readout
2027-12-23 · 1.7y away
Parkinson's
Ph3 Readout
2029-01-12 · 2.8y away
CTCL
Ph3 Readout
2031-04-08 · 5.0y away
Parkinson's
RecruitingNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04613495 | Phase 3 | Parkinson's | Recruiting | 2893 | DAS28 |
| NCT08767975 | Phase 3 | CTCL | Recruiting | 228 | SeizFreq |
| NCT08330908 | Phase 3 | Parkinson's | Recruiting | 538 | ORR |
| NCT03820284 | Phase 3 | Parkinson's | Not yet recr... | 852 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 |